Humalog Tempo Pen (Insulin Lispro)

Humalog Tempo Pen is indicated for the management of blood glucose in adults and children with diabetes.

• Rapid‑acting insulin therapy for type 1 diabetes mellitus.
• Supplemental mealtime insulin for type 2 diabetes mellitus when diet and oral agents are insufficient.
• Post‑prandial glucose control in patients requiring flexible dosing.
• Use in combination with basal insulin to achieve a basal‑bolus regimen.
• Adjusted for use during pregnancy or breastfeeding only under medical supervision.
• Can be used in pediatric patients as young as two years old when rapid insulin is required.

• Insulin lispro is a rapid‑acting insulin analog that differs from human insulin by two amino‑acid substitutions, reducing its tendency to form hexamers. After subcutaneous injection, lispro quickly dissociates into monomers, allowing rapid absorption into the bloodstream. It binds to insulin receptors on muscle and adipose cells, activating the receptor’s tyrosine kinase pathway, which promotes translocation of GLUT‑4 transporters and enhances glucose uptake, while also inhibiting hepatic glucose production.

Adverse reactions to Humalog Tempo Pen are reported across a range of frequencies and severities.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is reduced.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as small lumps or indentations at the injection site.
• Transient nausea or abdominal discomfort.
• Weight gain due to increased caloric storage when insulin dosing exceeds metabolic needs.
• Headache or dizziness, often related to fluctuating blood glucose levels.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Edema or heart failure exacerbation in patients with pre‑existing cardiac disease.

When prescribing or using Humalog Tempo Pen, several precautions should be considered to ensure safe and effective therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Monitor blood glucose closely during initiation, dose changes, or when sick.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in patients with known hypersensitivity to insulin lispro or any excipients.
• Consider pregnancy, lactation, and pediatric status; adjust dosing only under medical guidance.
• Review concomitant medications that may mask hypoglycemia symptoms.
• Store the pen at controlled temperature and discard after the indicated period once opened.
• Inspect the pen for damage or leakage before each use; do not use if the cartridge appears compromised.

Humalog Tempo Pen may interact with other agents that affect glucose metabolism or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• High‑dose beta‑blockers that can mask hypoglycemia symptoms.
• Systemic corticosteroids that increase insulin resistance.
• Use of MAO inhibitors is not recommended as they may interfere with glucose regulation.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia.
• Alcohol consumption, especially in excess, which may cause delayed hypoglycemia.
• Thyroid hormone therapy, as hyperthyroidism can increase insulin clearance.
• Loop diuretics, which may affect potassium levels and insulin sensitivity.
• Concurrent use of growth hormone therapy may increase insulin requirements.